March 27th 2023
Here's some of what is coming soon to NeurologyLive® this week.
March 26th 2023
March 26th 2023
Treatment Advancements to Overcome Barriers in the Management of Schizophrenia: Key Considerations for Pharmacists
1.5 Credit / Neurology, Psychiatry
Novel Treatment Approaches for Alzheimer Disease: Considerations for Pharmacists Across Care Settings
1.5 Credits / Neurology
Seizure Clusters: A Review of New Drug Delivery Methods and Emerging Therapy Options
0.50 Credit / Neurology
Novel Non-stimulant ADHD Treatments: A Review for Pharmacists
0.75 Credit / Neurology, Psychiatry
Treatment of Duchenne Muscular Dystrophy: Updates in Disease-Modifying Drugs
0.75 Credit / Neurology
Therapeutic Strategies for Bipolar Disorder: Recognizing the Intricacies in Disease Management and Considerations for Pharmacists Across Practice Settings
2.0 Credits / Neurology, Psychiatry
Strategies to Improve the Management of Migraine: Clinical Updates for Pharmacists and Patient-Case Review
1.0 Credit / Neurology
Recognizing Rett Syndrome: Managed Care Insights on Disease Burden
1.5 Credits / Neurology, Rare Diseases
Depression History Shows No Impact on Efficacy, Safety of Solriamfetol in Treating Obstructive Sleep Apnea, NarcolepsyMarch 24th 2023
Results of solriamfetol were similar when outcomes were examined in subgroups of concomitant antidepressant use, regardless of depression history, indicating that antidepressants did not affect the efficacy of the drug.
Losmapimod Demonstrates Significant Slowing of Facioscapulohumeral Muscular Dystrophy Over Long-Term PeriodMarch 23rd 2023
Durability of treatment response on reachable workspace was observed among those who continued losmapimod throughout the 96-week period and those who switched from placebo.
Myasthenia Agent Zilucoplan Continues to Show Positive Efficacy in Long-Term ExtensionMarch 23rd 2023
In participants who received placebo during the parent studies, rapid improvements were observed as early as week 1 after switching to zilucoplan, and continued through week 12 of the extension period.
Consensus Considerations Developed for SRP-9001 Adverse Event Management in DMDMarch 23rd 2023
The 12-person Dephi panel reviewed data from 3 clinical trials of delandistrogene maxeparvovec (SRP-9001; Sarepta), and developed considerations for the management of vomiting, myocarditis, acute liver injury, and immune-mediated myositis.
FDA Issues Complete Response Letter for AbbVie’s 24-Hour Continuous Carbidopa/Levodopa PumpMarch 22nd 2023
If approved, ABBV-951 will become the first subcutaneous delivery of carbidopa/levodopa, often considered the standard of care for symptom management for patients with Parkinson disease.
NeuroVoices: Emma Ciafaloni, MD, on Mounting Progress in the Neuromuscular Field, Duchenne Muscular DystrophyMarch 22nd 2023
The professor of neurology and pediatrics at University of Rochester Medical Center shared her thoughts on the 2023 MDA Clinical and Scientific Conference, and the progress made in the treatment of neuromuscular disorders.
Post-Hoc Analysis of CHAMPION MG Study Highlights Ravulizumab’s Effects on Specific Muscle DomainsMarch 21st 2023
After previously showing positive effects on MG-ADL and QMG, ravulizumab continued to show improvements in ocular and respiratory muscle domains in myasthenia gravis.
FDA Potentially Mulling Neurofilament Light as Critical Biomarker in Upcoming AdComm Meeting of TofersenMarch 20th 2023
In a phase 3 study, tofersen failed to meet its primary end point of functional change, but did meet its target engagement of SOD1 protein and reductions in neurofilament light.
Minor Differences in Inclusion Criteria, Baseline Characteristics Impact Motor and Nonmotor Clinical Outcomes in Presymptomatic Spinal Muscular AtrophyMarch 20th 2023
Differences in baseline characteristics and eligible criteria in presymptomatic infants with spinal muscular atrophy led to differential results on motor and nonmotor clinical outcomes.
A Balancing Challenge: Social Relationships in the Life of Adolescents With NarcolepsyMarch 19th 2023
Anne Marie Morse, DO, a pediatric neurologist and sleep medicine specialist at Geisinger Medical Center, talked about the challenges that adolescents with narcolepsy face in their social relationships.
NeurologyLive® Brain Games: March 19, 2023March 19th 2023
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of the Muscular Dystrophy Association (MDA).
FDA to Hold AdComm Meeting on Investigational DMD Treatment SRP-9001March 18th 2023
The FDA has reversed course, deciding to hold an advisory committee meeting ahead of the May 29, 2023, action date for Sarepta’s investigational DMD agent SRP-9001 (also known as delandistrogene moxeparvovec).